Translational Neural Devices (R61/R33 - Clinical Trial Optional)
National Institutes of Health · Opportunity PAR-25-053
Who can apply
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities
- Native American tribal organizations (other)
- Nonprofits with 501(c)(3), other than higher education
- Nonprofits without 501(c)(3)
- Private institutions of higher education
- For-profit organizations other than small businesses
- Small businesses
- Others
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
About this opportunity
The purpose of this Notice of Funding Opportunity (NOFO) is to encourage investigators to pursue translational activities and small clinical studies to advance the development of therapeutic, and diagnostic devices for disorders that affect the nervous or neuromuscular systems. Activities supported in this program include implementation of clinical prototype devices, non-clinical safety and efficacy testing, design verification and validation activities, obtaining an Investigational Device Exemption (IDE) for a Significant Risk (SR) study or Institutional Review Board (IRB) approval for a Non-Significant Risk (NSR) study, as well as a subsequent small clinical study. The clinical study is expected to provide information about the device function or final design that cannot be practically obtained through additional non-clinical assessments (e.g., bench top or animal studies) due to the novelty of the device or its intended use. This NOFO is a milestone-driven cooperative agreement program and will involve participation of NIH program staff in negotiating the final project plan before award and monitoring of research progress.
Award history — this exact opportunity
NIH RePORTER lists 3 funded awards under PAR-25-053 across 3 organizations.
Total award obligations, not per-year amounts.
Recent awardees include: CLEVELAND VA MEDICAL RESEARCH/ED/FDN, WASHINGTON UNIVERSITY, UNIVERSITY OF COLORADO DENVER.
Source: NIH RePORTER, matched on the exact opportunity number. NIH publishes success rates by institute and activity code — source.
Portfolio context — this listing covers more than this opportunity
This opportunity is funded under Assistance Listing 93.853 (“Extramural Research Programs in the Neurosciences and Neurological Disorders”), a broad federal program that made about 1102 new awards per year over the last five fiscal years (median award $457k). Those figures describe that whole portfolio — not this specific solicitation, so we don't show them as if they were this opportunity's track record.
Applicant counts per solicitation are not published by any federal agency — no one can honestly sell you that number. NIH publishes success rates by institute and activity code — source.
Don't want to hunt for grants like this one? Get free deadline alerts for your state and focus areas.
Consultant or grant writer? See the client-ready Opportunity Brief for this grant — actual award sizes vs. the advertised ceiling, who wins, printable "prepared for your client" version.
Similar grants still open
| Opportunity | Agency | Deadline | Award ceiling | Eligible |
|---|---|---|---|---|
| NIH Director’s Pioneer Award (DP1 Clinical Trial Optional) | National Institutes of Health | September 9, 2026 0d left | $700k | Nonprofits |
| Fiscal Year 2027 Expanding Nutrition Services | Health Resources and Services Administration | September 9, 2026 0d left | $350k | |
| NIH Director’s Early Independence Award (DP5 Clinical Trial Optional) | National Institutes of Health | September 10, 2026 1d left | $350k | Nonprofits |
| Improving the Capacity of Tribal Communities to Identify Emerging Drug Threats | Office of National Drug Control Policy | September 13, 2026 4d left | $300k | Nonprofits |